Heinz Reichmann (Universitätsklinikum Carl Gustav Carus, Dresden, Germany) shares key findings and expert insights into the OPTIPARK study, a prospective, open-label, uncontrolled, single-group, multi-centre trial in patients with Parkinson’s disease and wearing-off motor fluctuations (ClinicalTrials.gov Identifier: NCT02847442).
Questions
1. What were the aims and design of the OPTIPARK study? (0:05)
2. What were the efficacy and safety findings of the study? (2:24)
3. What were the major strengths and weaknesses of this study? (4:49)
Also see linked video: Heinz Reichmann, EAN 2020 – Unmet Needs in the Treatment of Parkinson’s
Speaker disclosure: Heinz Reichmann reports having received honoraria from Bial for his participation in advisory board meetings and satellite symposia.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
